Suppression of the hypothalamic–pituitary–gonadal axis by TAK-385 (relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: Studies in human GnRH receptor knock-in mice-Reference-Cited by-同舟云学术

Suppression of the hypothalamic–pituitary–gonadal axis by TAK-385 (relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: Studies in human GnRH receptor knock-in mice

Published:2014-01 Issue: Volume:723 Page:167-174
ISSN:0014-2999
Container-title:European Journal of Pharmacology
language:en
Short-container-title:European Journal of Pharmacology

Author:

Nakata Daisuke,Masaki Tsuneo,Tanaka Akira,Yoshimatsu Mie,Akinaga Yumiko,Asada Mari,Sasada Reiko,Takeyama Michiyasu,Miwa Kazuhiro,Watanabe Tatsuya,Kusaka Masami

Publisher

Elsevier BV

Subject

Pharmacology

Reference21 articles.

1. Overlapping, nonidentical binding sites of different classes of nonpeptide antagonists for the human gonadotropin-releasing hormone receptor;Betz;J. Med. Chem.,2006

2. GnRH agonists and uterine leiomyomas;Broekmans;Hum. Reprod.,1996

3. ClinicalTrials.gov. Active elagolix clinical trials. 〈http://www.clinicaltrials.gov/ct2/results?term=elagolix〉 (accessed 15.11.13).

4. Gonadotropin-releasing hormone and the control of gonadotrope function;Counis;Reprod. Nutr. Dev.,2005

5. Degarelix for prostate cancer;Doehn;Expert Opin. Investig. Drugs,2009

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Why do oestrogens matter: systematic review and meta-analysis assessing GnRH antagonists, considering add-back therapy, for endometriosis-associated pain;Reproductive BioMedicine Online;2024-10

2. Impact of relugolix combination therapy on functioning and quality of life in women with endometriosis-associated pain;Fertility and Sterility;2024-06

3. Relugolix/Estradiol/Norethisterone Acetate: A Review in Endometriosis-Associated Pain;Drugs;2024-04

4. The clinical trial of alternative relugolix administration for uterine leiomyoma prior to surgically treatment: a study protocol for Non-Adverse Relugolix Administration (NARA) trial;Trials;2024-01-19

5. Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT open-label extension study;Human Reproduction;2024-01-18